鉴定 microRNA-451a 作为一种新型的结直肠癌诊断的循环生物标志物。
Identification of microRNA-451a as a Novel Circulating Biomarker for Colorectal Cancer Diagnosis.
机构信息
Department of Anesthesiology, Affiliated Cancer Hospital of ZhengZhou University, Henan Cancer Hospital, ZhengZhou, China.
Department of Laboratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
出版信息
Biomed Res Int. 2020 Aug 27;2020:5236236. doi: 10.1155/2020/5236236. eCollection 2020.
BACKGROUND
Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. Successful treatment of CRC relies on accurate early diagnosis, which is currently a challenge due to its complexity and personalized pathologies. Thus, novel molecular biomarkers are needed for early CRC detection.
METHODS
Gene and microRNA microarray profiling of CRC tissues and miRNA-seq data were analyzed. Candidate microRNA biomarkers were predicted using both CRC-specific network and miRNA-BD tool. Validation analyses were carried out to interrogate the identified candidate CRC biomarkers.
RESULTS
We identified miR-451a as a potential early CRC biomarker circulating in patient's serum. The dysregulation of miR-451a was revealed both in primary tumors and in patients' sera. Downstream analysis validated the tumor suppressor role of miR-451a and high sensitivity of miR-451a in CRC patients, further confirming its potential role as CRC circulation biomarker.
CONCLUSION
The miR-451a is a potential circulating biomarker for early CRC diagnosis.
背景
结直肠癌（CRC）是全球癌症死亡的主要原因之一。CRC 的成功治疗依赖于准确的早期诊断，但其复杂性和个体化的病理特征使其成为一个挑战。因此，需要新的分子生物标志物来进行早期 CRC 检测。
方法
分析 CRC 组织的基因和 microRNA 微阵列谱以及 miRNA-seq 数据。使用 CRC 特异性网络和 miRNA-BD 工具预测候选 microRNA 生物标志物。进行验证分析以检测鉴定的候选 CRC 生物标志物。
结果
我们发现 miR-451a 是一种潜在的循环于患者血清中的早期 CRC 生物标志物。miR-451a 在原发性肿瘤和患者血清中均存在失调。下游分析验证了 miR-451a 的肿瘤抑制作用及其在 CRC 患者中的高灵敏度，进一步证实了其作为 CRC 循环生物标志物的潜在作用。
结论
miR-451a 是早期 CRC 诊断的潜在循环生物标志物。
Zotero 插件